CTLA4 and head and neck squamous cell carcinoma: In conclusion, although the combination of MC chemotherapy with dual anti-PD-L1/anti-CTLA-4 immunotherapy may offer a valuable treatment option, patients with HNSCC derive moderate benefit from this strategy, comparable to that observed with single ICI in these tumors.